论文部分内容阅读
为了改进高危Ⅲ期多发性骨髓瘤(MM)的疗效和生存期,瑞典中心骨髓瘤组自1981年始对86例未经治疗的Ⅲ期 MM 患者,进行两种化疗方案随机化的治疗研究。病人和方法 VMCP/VBAP 组42例,年龄≤65岁者17例,≥65岁者25例;MP 组44例,年龄≤65岁者15例,≥65岁者29例。VMCP 方案为:长春新碱1mg 静注第1天;马法兰5mg/M~2/d 口服第1～4天;环磷酰胺100mg/M~2/d 口服第1～4天;强的松100mg/M~2/d 口服第1～3天。VBAP 方案为:长春新碱1mg 静注第1天;卡氮芥30mg/M~2静注第1天;阿霉素25mg/M~2静注第1天;强的松60mg/M~2/d 口
To improve the efficacy and survival of high-risk stage III multiple myeloma (MM), a randomized study of two chemotherapy regimens was conducted in 86 patients with untreated stage III MM in the Swedish Center for Myeloma. Patients and Methods VMCP / VBAP group 42 cases, 17 cases of age ≤ 65 years, ≥ 65 years in 25 cases; MP group 44 cases, age ≤ 65 years in 15 cases, ≥ 65 years in 29 cases. VMCP regimen: vincristine 1mg intravenous 1 day; melphalan 5mg / M ~ 2 / d orally for 1 to 4 days; cyclophosphamide 100mg / M ~ 2 / d orally for 1 to 4 days; prednisone 100mg / M ~ 2 / d orally for the first 3 days. VBAP regimen: vincristine 1mg intravenously on day 1; carmustine 30mg / M ~ 2 intravenous on day 1; doxorubicin 25mg / M ~ 2 intravenous on day 1; prednisone 60mg / M ~ 2 / d mouth